EcoDrugPlus

Ribosomal Protein Lateral Stalk Subunit P0

Ensembl ID : ENSBTAG00000017389
Gene Symbol: RPLP0
15 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Ribosomal Protein Lateral Stalk Subunit P1

Ensembl ID : ENSBTAG00000018320
Gene Symbol: RPLP1
15 Enzyme and pathways 5 Cross references
271 Possible Orthologues:

Secretin Receptor

Ensembl ID : ENSBTAG00000013619
Gene Symbol: SCTR
7 Enzyme and pathways 5 Cross references
142 Possible Orthologues:

Selectin E

Ensembl ID : ENSBTAG00000007307
Gene Symbol: SELE
2 Enzyme and pathways 5 Cross references
255 Possible Orthologues:

Selectin L

Ensembl ID : ENSBTAG00000011515
Gene Symbol: SELL
4 Cross references
98 Possible Orthologues:

Selectin P

Ensembl ID : ENSBTAG00000020755
Gene Symbol: SELP
5 Enzyme and pathways 5 Cross references
131 Possible Orthologues:

Serpin Family C Member 1

Ensembl ID : ENSBTAG00000004362
Gene Symbol: SERPINC1
8 Enzyme and pathways 5 Cross references
212 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSBTAG00000015804
Gene Symbol: SIGMAR1
5 Cross references
217 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSBTAG00000014023
Gene Symbol: SIRT1
12 Enzyme and pathways 5 Cross references
171 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSBTAG00000013287
Gene Symbol: SMO
9 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSBTAG00000002631
Gene Symbol: SCNN1A
6 Enzyme and pathways 5 Cross references
165 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSBTAG00000012290
Gene Symbol: SCNN1B
6 Enzyme and pathways 5 Cross references
163 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).